{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:32:29Z","timestamp":1778923949698,"version":"3.51.4"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0165102","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T19:02:01Z","timestamp":1479236521000},"page":"e0165102","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Integrated Genomics Identifies miR-32\/MCL-1 Pathway as a Critical Driver of Melanomagenesis: Implications for miR-Replacement and Combination Therapy"],"prefix":"10.1371","volume":"11","author":[{"given":"Prasun J.","family":"Mishra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravin J.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Merlino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"issue":"18","key":"ref1","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"KT Flaherty","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"7326","key":"ref2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"R Nazarian","year":"2010","journal-title":"Nature"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"RJ Sullivan","year":"2013","journal-title":"European journal of cancer"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/CJI.0b013e31828eed39","article-title":"Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma","volume":"36","author":"S Wilgenhof","year":"2013","journal-title":"Journal of immunotherapy"},{"issue":"26","key":"ref5","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"JR Brahmer","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"26","key":"ref6","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"SL Topalian","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1073\/pnas.94.2.701","article-title":"Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor\/scatter factor","volume":"94","author":"H Takayama","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"ref8","doi-asserted-by":"crossref","first-page":"10968","DOI":"10.1073\/pnas.0611638104","article-title":"ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence","volume":"104","author":"L Ha","year":"2007","journal-title":"P Natl Acad Sci USA"},{"issue":"22","key":"ref9","first-page":"6724","article-title":"Ink4a\/arf deficiency promotes ultraviolet radiation-induced melanomagenesis","volume":"62","author":"JA Recio","year":"2002","journal-title":"Cancer research"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"JA Curtin","year":"2005","journal-title":"The New England journal of medicine"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1101\/gad.1437206","article-title":"Malignant melanoma: genetics and therapeutics in the genomic era","volume":"20","author":"L Chin","year":"2006","journal-title":"Genes & development"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djn157","article-title":"Frequent p16-independent inactivation of p14ARF in human melanoma","volume":"100","author":"DE Freedberg","year":"2008","journal-title":"Journal of the National Cancer Institute"},{"issue":"6851","key":"ref13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/35092592","article-title":"Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis","volume":"413","author":"NE Sharpless","year":"2001","journal-title":"Nature"},{"issue":"6853","key":"ref14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/35095108","article-title":"Neonatal sunburn and melanoma in mice","volume":"413","author":"FP Noonan","year":"2001","journal-title":"Nature"},{"issue":"7331","key":"ref15","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature09666","article-title":"Interferon-gamma links ultraviolet radiation to melanomagenesis in mice","volume":"469","author":"MR Zaidi","year":"2011","journal-title":"Nature"},{"issue":"33","key":"ref16","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.0706217104","article-title":"A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance","volume":"104","author":"PJ Mishra","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1242\/dev.121.5.1547","article-title":"A cloned, immortal line of murine melanoblasts inducible to differentiate to melanocytes","volume":"121","author":"EV Sviderskaya","year":"1995","journal-title":"Development"},{"issue":"26","key":"ref18","doi-asserted-by":"crossref","first-page":"10968","DOI":"10.1073\/pnas.0611638104","article-title":"ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence","volume":"104","author":"L Ha","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"ref19","doi-asserted-by":"crossref","first-page":"e8445","DOI":"10.1371\/journal.pone.0008445","article-title":"MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism","volume":"4","author":"PJ Mishra","year":"2009","journal-title":"PLOS ONE"},{"issue":"7130","key":"ref20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"V Gray-Schopfer","year":"2007","journal-title":"Nature"},{"issue":"16","key":"ref21","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/onc.2009.521","article-title":"Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation","volume":"29","author":"PJ Mishra","year":"2010","journal-title":"Oncogene"},{"issue":"Suppl 6","key":"ref22","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1186\/1471-2105-10-S6-S20","article-title":"Human microRNA target analysis and gene ontology clustering by GOmir, a novel stand-alone application","volume":"10","author":"MG Roubelakis","year":"2009","journal-title":"BMC bioinformatics"},{"issue":"8","key":"ref23","first-page":"1865","article-title":"Expression of apoptosis regulators in cutaneous malignant melanoma","volume":"4","author":"L Tang","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1261\/rna.031831.111","article-title":"miR-Sens\u2014a retroviral dual-luciferase reporter to detect microRNA activity in primary cells","volume":"18","author":"E Beillard","year":"2012","journal-title":"RNA"},{"issue":"14","key":"ref25","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"72","author":"WC Reinhold","year":"2012","journal-title":"Cancer Res"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1158\/0008-5472.CAN-03-1045","article-title":"expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53","volume":"64","author":"PG Magro","year":"2004","journal-title":"Cancer research"},{"issue":"20","key":"ref27","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","article-title":"Apoptosis and melanoma chemoresistance","volume":"22","author":"MS Soengas","year":"2003","journal-title":"Oncogene"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/jm1001265","article-title":"BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma\/leukemia-2 (Bcl-2) family proteins","volume":"53","author":"J Wei","year":"2010","journal-title":"J Med Chem"},{"issue":"46","key":"ref29","doi-asserted-by":"crossref","first-page":"39829","DOI":"10.1074\/jbc.M111.305326","article-title":"Identification of a novel Mcl-1 protein binding motif","volume":"286","author":"WJ Placzek","year":"2011","journal-title":"J Biol Chem"},{"issue":"21","key":"ref30","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1073\/pnas.1100769108","article-title":"Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7\/IL-24-mediated toxicity","volume":"108","author":"R Dash","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7315","key":"ref31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nature09454","article-title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","volume":"467","author":"G Bollag","year":"2010","journal-title":"Nature"},{"issue":"2","key":"ref32","article-title":"MicroRNA-32 functions as a tumor suppressor and directly targets EZH2 in uveal melanoma","volume":"15","author":"YB Ma","year":"2016","journal-title":"Genet Mol Res"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/exd.12254","article-title":"Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma","volume":"22","author":"CS McKee","year":"2013","journal-title":"Exp Dermatol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2007-05-089037","article-title":"The Akt\/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells","volume":"111","author":"PG Longo","year":"2008","journal-title":"Blood"},{"issue":"16","key":"ref35","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1158\/0008-5472.CAN-09-4471","article-title":"Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells","volume":"70","author":"Y Shao","year":"2010","journal-title":"Cancer research"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbamcr.2006.11.009","article-title":"Clinical experience of MEK inhibitors in cancer therapy","volume":"1773","author":"D Wang","year":"2007","journal-title":"Biochimica et biophysica acta"},{"issue":"9","key":"ref37","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/onc.2013.45","article-title":"Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor","volume":"33","author":"TM Becker","year":"2014","journal-title":"Oncogene"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1541-7786.MCR-08-0358","article-title":"Mcl-1 is required for melanoma cell resistance to anoikis","volume":"7","author":"K Boisvert-Adamo","year":"2009","journal-title":"Molecular cancer research: MCR"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0165102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T18:42:25Z","timestamp":1657737745000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0165102"}},"subtitle":[],"editor":[{"given":"Soheil S.","family":"Dadras","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,15]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0165102","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]}}}